National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 4 of 4 Research Studies DisplayedChou R, Dana T, Blazina I
Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US Preventive Services Task Force.
The purpose of this report systematically reviewed benefits and harms of statins for prevention of cardiovascular disease (CVD), in order to inform the US Preventive Services Task Force. It concluded that in adults at increased CVD risk but without prior CVD events, statin therapy was associated with reduced risk of all-cause and cardiovascular mortality and CVD events, with greater absolute benefits in patients at greater baseline risk.
AHRQ-funded; 2902012000015I.
Citation: Chou R, Dana T, Blazina I .
Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US Preventive Services Task Force.
JAMA 2016 Nov 15;316(19):2008-24. doi: 10.1001/jama.2015.15629.
.
.
Keywords: U.S. Preventive Services Task Force (USPSTF), Prevention, Cardiovascular Conditions, Medication, Evidence-Based Practice
McNellis RJ, Beswick-Escanlar V
AHRQ Author: McNellis RJ
Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer.
This case study involves a a 55-year-old man who presents to your office for a routine refill of his antihypertension medication, his 65-year-old brother who also visits you to ask about taking low-dose aspirin, and his 55-year-old wife, also your patient, who recently experienced abdominal pain,. It poses three multiple choice questions focused on the use of low-dose aspirin, together with the U.S. Preventive Services Task Force recommendations and related background information.
AHRQ-authored.
Citation: McNellis RJ, Beswick-Escanlar V .
Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer.
Am Fam Physician 2016 Oct 15;94(8):661-62.
.
.
Keywords: Cancer: Colorectal Cancer, Cardiovascular Conditions, Medication, Prevention, U.S. Preventive Services Task Force (USPSTF), Case Study
Guirguis-Blake JM, Evans CV, Senger CA
Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force.
This is an update of a systematic review about the benefits of aspirin for the primary prevention of cardiovascular events in adults aged 40 years or older and to evaluate effect modification in subpopulations. It concluded that the beneficial effect of aspirin for the primary prevention of CVD is modest and also occurs at doses of 100 mg or less per day. Older adults seem to achieve a greater relative MI benefit.
AHRQ-funded; 290201200015.
Citation: Guirguis-Blake JM, Evans CV, Senger CA .
Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force.
Ann Intern Med 2016 Jun 21;164(12):804-13. doi: 10.7326/m15-2113.
.
.
Keywords: U.S. Preventive Services Task Force (USPSTF), Cardiovascular Conditions, Medication, Risk, Prevention
Chubak J, Whitlock EP, Williams SB
Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force.
The researchers conducted systematic reviews of aspirin and 1) total cancer mortality and incidence in persons eligible for primary prevention of cardiovascular disease (CVD) and 2) colorectal cancer (CRC) mortality and incidence in persons at average CRC risk.. Evidence from CVD primary and secondary prevention studies suggested that aspirin therapy reduces CRC incidence and perhaps mortality approximately 10 years after initiation.
AHRQ-funded; 290201200151I.
Citation: Chubak J, Whitlock EP, Williams SB .
Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force.
Ann Intern Med 2016 Jun 21;164(12):814-25. doi: 10.7326/m15-2117.
.
.
Keywords: Cancer: Colorectal Cancer, Cardiovascular Conditions, Medication, Mortality, U.S. Preventive Services Task Force (USPSTF)